Stocks in Frontline Trades’ Choice: Delek US Holdings (NYSE:DK), Allergan (NYSE:AGN)

Shares of Delek US Holdings, Inc. (NYSE:DK) [Trend Analysis] runs in leading trade, it moving up 4.99% to traded at $25.27. The firm has price volatility of 2.37% for a week and 3.17% for a month. Its beta stands at 1.84 times. Delek US Holdings Inc. (DK) along with Alon USA Energy, Inc. (ALJ) reported that a definitive contract by which Delek US will acquire all of the outstanding shares of Alon common stock which Delek US does not already own in an all-stock transaction.Based on a closing price of $24.07 per share for Delek US common stock on December 30, 2016, the implied price for Alon common stock is $12.13 per share, or $464 million in equity value for the remaining shares.

The enterprise value of this transaction to acquire the remaining 53 percent of Alon shares of common stock not already owned by Delek US is approximately $675 million including the proportionate assumption of $152 million of net debt related to this transaction and $59 million of market value for the non-controlling interest in Alon USA Partners, LP (ALDW). Narrow down four to firm performance, its weekly performance was -0.78% and monthly performance was 19.69%. The stock price of DK is moving up from its 20 days moving average with 6.13% and isolated positively from 50 days moving average with 25.31%.

Several matter pinch shares of Allergan plc (NYSE:AGN) [Trend Analysis], as shares moving up 2.94% to $216.19 with a share volume of 5.13 Million. A global investor rights law firm, Rosen Law Firm, reported the filing of a class action lawsuit on behalf of purchasers of the securities of Allergan plc (NYSE:AGN) and/or Actavisplc from February 25, 2014 through November 3, 2016, both dates inclusive.

The lawsuit seeks recovery of investor losses. The action filed by the firm is pending in the U.S. District Court for the District of New Jersey.According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Allergan and Actavis were engaging and/or had engaged in conduct that would result in an antitrust investigation by the U.S. Department of Justice; (2) the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against Allergan and Actavis by the end of 2016 for suspected price collusion; (3) in turn, Allergan and Actavis lacked effective internal controls; and (4) as a result, Allergan plc’s and Actavisplc’s public statements were materially false and misleading at all relevant times The stock is going forward its 52-week low with 17.18% and moving down from its 52-week high price with -31.38%. To have technical analysis views, liquidity ratio of a company was calculated 4.00 as evaluated with its debt to equity ratio of 0.39. The float short ratio was 6.75%, as compared to sentiment indicator; Short Ratio was 4.99.

 

About Aaron Smithies

Aaron Smithies has a wide look on current monetary and financial events. He is an editor and a writer. His views; At Streetwise Report, we think the best opportunities arise from a complete understanding of all investing disciplines in order to identify the most attractive stocks at any given time. Interests: Biotech, Finical markets, Dividend stock ideas & income, Energy stocks, Consumer goods stocks

Leave a Reply

Your email address will not be published. Required fields are marked *